ym 529 has been researched along with Bone Fractures in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Akagi, Y; Matushima, S; Ogata, N; Ogata, S; Sudou, T; Sugihara, R; Takao, Y; Toh, U; Watanabe, H | 1 |
| Abe, A; Hasegawa, E; Ishikawa, H; Ito, S; Kobayashi, D; Murasawa, A; Nakazono, K; Narita, I; Nomura, Y; Otani, H; Takai, C | 1 |
| Morio, Y; Tanishima, S | 1 |
| Amano, N; Honda, Y; Iwamoto, J; Sato, Y | 1 |
| Fukunaga, M; Hagino, H; Matsumoto, T; Morii, H; Nakamura, T; Nakano, T; Ohashi, Y; Shiraki, M; Takaoka, K | 1 |
| Fujimori, J; Kubo, T; Matsuo, T; Ochi, M; Shimose, S | 1 |
| Takata, S | 1 |
2 review(s) available for ym 529 and Bone Fractures
| Article | Year |
|---|---|
A review of minodronic acid hydrate for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures | 2013 |
[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Drug Design; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Research | 2007 |
2 trial(s) available for ym 529 and Bone Fractures
| Article | Year |
|---|---|
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risedronic Acid | 2013 |
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Body Height; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Spinal Fractures; Treatment Outcome | 2009 |
3 other study(ies) available for ym 529 and Bone Fractures
| Article | Year |
|---|---|
Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Postmenopause | 2022 |
The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Glucocorticoids; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome | 2018 |
Minodronate for the treatment of osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Dogs; Drug Evaluation, Preclinical; Female; Fractures, Bone; Haplorhini; Humans; Imidazoles; Osteoporosis; Rats | 2010 |